Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUGQIV)

Drug Name
2-chloro-5-nitro-N-phenylbenzamide Drug Info
Synonyms
2-Chloro-5-nitro-N-phenylbenzamide; GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
644213
ChEBI ID
CHEMBL79993
CAS Number
CAS 22978-25-2
TTD Drug ID
DMUGQIV
INTEDE Drug ID
DR2165

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PPAR-gamma messenger RNA (PPARG mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [8]
AD-5075 DM1SLJ9 Type-2 diabetes 5A11 Terminated [9]
L-783483 DM6OTGE Discovery agent N.A. Investigative [10]
LG100754 DMEK4FY Discovery agent N.A. Investigative [11]
L-796449 DMWTGQM Discovery agent N.A. Investigative [12]
L-165461 DMKBSGN Discovery agent N.A. Investigative [12]
AD-5061 DM5WV13 Discovery agent N.A. Investigative [13]
TZD18 DMVCHOX Discovery agent N.A. Investigative [14]
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN Discovery agent N.A. Investigative [15]
reglitazar DMQ3ER0 Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Retinoic acid receptor RXR-alpha (RXRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [17]
Bexarotene DMOBIKY Cutaneous T-cell lymphoma 2B01 Approved [18]
AGN-34 DM5ECDM Discovery agent N.A. Investigative [19]
LG100754 DMEK4FY Discovery agent N.A. Investigative [20]
(5BETA)-PREGNANE-3,20-DIONE DMVQ6RN Discovery agent N.A. Investigative [1]
phytanic acid DMSZ1RB Discovery agent N.A. Investigative [21]
CD3254 DM38MU1 Discovery agent N.A. Investigative [22]
UVI3003 DM95UI1 Discovery agent N.A. Investigative [23]
Tributylstannanyl DMHN7CB Discovery agent N.A. Investigative [1]
methoprene acid DM58A0W Discovery agent N.A. Investigative [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [25]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [26]
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [27]
Rosiglitazone XR DMT45MU Type-2 diabetes 5A11 Approved [28]
Thiazolidinedione DMC1NBW Alzheimer disease 8A20 Approved [26]
Glitazone DMDN4A1 N. A. N. A. Phase 4 [29]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [30]
Rivoglitazone DMBY31K Ocular inflammation 9C61.24 Phase 3 [31]
Balaglitazone DMXBHR6 Type-1 diabetes 5A10 Phase 3 [32]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Oxygen-insensitive NADPH nitroreductase B (nfsB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AI3-23606 DMHMT49 N. A. N. A. Phase 1 [34]
Nitroimidazole DMMY2S5 Trypanosomiasis 1D51-1F53 Investigative [34]
CL-205086 DMB6XUY N. A. N. A. Investigative [34]
Drug(s) Metabolized By Oxygen-insensitive NADPH nitroreductase A (nfsA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ornidazole DM6QHDJ Amoebiasis 1A36 Approved [35]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [35]
AI3-23606 DMHMT49 N. A. N. A. Phase 1 [34]
Nitroimidazole DMMY2S5 Trypanosomiasis 1D51-1F53 Investigative [34]
CL-205086 DMB6XUY N. A. N. A. Investigative [34]
Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Fluoxetine DM3PD2C Bipolar depression Approved [39]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [40]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [41]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [44]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sterol 26-hydroxylase, mitochondrial (CYP27A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [40]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [47]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [48]
Testosterone DM7HUNW Hot flushes GA30 Approved [49]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [50]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [52]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By T-lymphocyte activation antigen CD80 (CD80)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [55]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [56]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [57]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [58]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [7]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [59]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [7]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [60]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4V2 (CYP4V2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [62]
Methotrexate DM2TEOL Anterior urethra cancer Approved [63]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [64]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [57]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [65]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [66]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [67]
Urethane DM7NSI0 N. A. N. A. Phase 4 [68]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [70]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [70]
Gefitinib DM15F0X Colon adenocarcinoma Approved [71]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [72]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [73]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [74]
Methotrexate DM2TEOL Anterior urethra cancer Approved [75]
Quercetin DM3NC4M Obesity 5B81 Approved [76]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [77]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [78]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Inhibitor [1]
PPAR-gamma messenger RNA (PPARG mRNA) TTT2SVW PPARG_HUMAN Inhibitor [2]
Retinoic acid receptor RXR-alpha (RXRA) TT6PEUO RXRA_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Oxygen-insensitive NADPH nitroreductase A (nfsA) DEX5D46 NFSA_SALTY Substrate [3]
Oxygen-insensitive NADPH nitroreductase B (nfsB) DEOWDK1 NFSB_SALTY Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [4]
Cytochrome P450 4V2 (CYP4V2) OTQKNK0D CP4V2_HUMAN Gene/Protein Processing [5]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Gene/Protein Processing [6]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Gene/Protein Processing [6]
T-lymphocyte activation antigen CD80 (CD80) OTJBLUQE CD80_HUMAN Gene/Protein Processing [7]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
3 Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailability. Chem Biol Interact. 2012 Apr 15;197(1):16-22.
4 Concentration-dependent effects of chlorpyrifos oxon on peroxisome proliferator-activated receptor signaling in MCF-7 cells. Toxicol In Vitro. 2022 Feb;78:105268. doi: 10.1016/j.tiv.2021.105268. Epub 2021 Oct 29.
5 Expression of CYP4V2 in human THP1 macrophages and its transcriptional regulation by peroxisome proliferator-activated receptor gamma. Toxicol Appl Pharmacol. 2017 Sep 1;330:100-106. doi: 10.1016/j.taap.2017.07.009. Epub 2017 Jul 17.
6 Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgama and adenosine. Eur J Pharmacol. 2013 Jan 5;698(1-3):299-309.
7 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J Immunol. 2007 May 15;178(10):6130-9. doi: 10.4049/jimmunol.178.10.6130.
8 A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
9 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
10 Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
11 The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
12 Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
13 A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
14 A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
15 Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
16 Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
17 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19 Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
20 The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9.
21 Phytanic acid is a retinoid X receptor ligand. Eur J Biochem. 1996 Feb 15;236(1):328-33.
22 Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
23 Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators thro... J Biol Chem. 2005 Jan 14;280(2):1625-33.
24 Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6157-60.
25 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
26 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
27 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
28 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
29 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
30 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
31 A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
32 Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
33 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
34 Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
35 Identification and characterization of SnrA, an inducible oxygen-insensitive nitroreductase in Salmonella enterica serovar Typhimurium TA1535. Mutat Res. 2002 Oct 31;508(1-2):59-70.
36 Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
37 Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
38 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
39 Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
40 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
41 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
42 Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
43 Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
44 Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
45 Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
46 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
47 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
48 PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007 Feb;48(2):373-84.
49 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
50 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
51 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
52 Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
53 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
54 Differential expression of dendritic cell markers by all-trans retinoic acid on human acute promyelocytic leukemic cell line. Int Immunopharmacol. 2004 Dec 15;4(13):1587-601. doi: 10.1016/j.intimp.2004.07.010.
55 Suppression by (9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation. Toxicology. 2013 Aug 9;310:84-91. doi: 10.1016/j.tox.2013.05.009. Epub 2013 May 29.
56 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000 Mar 1;164(5):2405-11. doi: 10.4049/jimmunol.164.5.2405.
57 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
58 Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004 Jul;114(1):137-43. doi: 10.1016/j.jaci.2004.03.021.
59 Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol. 2009 Jul;37(7):838-48. doi: 10.1016/j.exphem.2009.04.003. Epub 2009 May 14.
60 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
61 Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28.
62 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
63 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
64 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
65 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
66 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
67 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
68 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
69 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
70 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
71 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
72 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
73 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
74 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
75 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
76 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
77 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
78 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.